WALTZ - Wet Age-Related Macular Degeneration (AMD) AL-39324 Treatment Examination

Inclusion Criteria: * Willing to give written informed consent, make the required study visits and follow instructions; * The study eye: * must have a primary diagnosis of choroidal neovascularization (CNV) secondary to AMD; * lesion must be no larger than 30 mm2; * must have edema measuring greater than 340 μm; * must have a visual score between 73 and 34 letters, inclusive; * must be able to have clear picture taken of the back of the eye; * Other protocol-defined inclusion criteria may apply. Exclusion Criteria: * The study eye must not have been treated for exudative AMD previously; * The study eye must not have any other ocular disease, condition, infection, or recent surgery that would interfere with vision or examination of the back of the eye; * The study eye must not have uncontrolled glaucoma; * The study eye must not be missing a lens; * Must not be taking any medication that is toxic to the lens; * Must not be taking oral or ocular corticosteroids; * Must not have an unstable or progressive condition that would interfere with study visits; * Must not have allergies to any component of the test article or sensitivity to fluorescein dye; * If female, must not be pregnant or nursing and must agree to adequate birth control; * Must not be participating in another drug or device study within 30 days of screening for this study; * Other protocol-defined exclusion criteria may apply.